Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines (Q40430523)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Cosette M Wheeler

1

object named as

Cosette M Wheeler

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Oliver M Bautista

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Joanne E Tomassini

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Margaret Nelson

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Carlos A Sattler

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Eliav Barr

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Protocol 11 study Investigators

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

5 December 2007

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

686-696

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

The causal relation between human papillomavirus and cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Epidemiology of Genital Human Papillomavirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Classification of papillomaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Immune responses to human papillomavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Introducing HPV vaccine in developing countries--key challenges and issues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Adolescent immunizations: a position paper of the Society for Adolescent Medicine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

CHAPTER 9 Delivering HPV vaccine in the industrial and developing world: the role of the ob-gyn community

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Combined hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Comparative analysis of two rates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.043

7 January 2021

Identifiers

10.1016/J.VACCINE.2007.11.043

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40430523&oldid=1897749544"